Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vistagen

< Previous 1 2 Next >
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at the Jefferies Global Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Stifel 2024 Virtual CNS Days
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Stifel 2023 Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Appoints Cindy Anderson as Chief Financial Officer
From Vistagen
Via Business Wire
Tickers VTGN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback